Le Lézard
Classified in: Health, Covid-19 virus
Subjects: SVY, CPG

COVID-19 Pandemic - The government presents its daily update


QUÉBEC CITY, Nov. 23, 2022 /CNW Telbec/ - The most recent data on the evolution of COVID-19, in the last 24 hours, in Québec show:

*Note that the number of cases listed is not representative of the situation since access to screening centres is restricted to priority clienteles.

Vaccination

To follow the evolution of the data on a daily basis, consult the open data or the INSPQ website at https://www.donneesquebec.ca/recherche/fr/organization/msss or at https://www.inspq.qc.ca/covid-19/donnees. Note that certain data, especially the number of cases, deaths and doses administered, may be subject to daily readjustment for previous days, given that a catch-up is necessary due to a delay in data entry.

A reminder concerning public health instructions:

To limit the spread of the coronavirus as much as possible, it is important to follow basic preventive measures such as hand washing, physical distancing, wearing a face covering and following the instructions in effect.

Remember that in the event of symptoms, it is always essential to isolate yourself and consult one of the self-care guides or call 1-877-644-4545 (or the telephone code corresponding to the region concerned) to find out the measures to be taken.

Related links:

SOURCE Ministère de la Santé et des Services sociaux


These press releases may also interest you

at 03:05
Skechers, The Comfort Technology Company®, has opened its first concept store in Brussels on its most famous shopping street, Rue Neuve. Together with its store on Antwerp's Meir and planned Bruges concept store opening in mid-May, the Company is...

at 03:01
SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") is pleased to provide an update on its significant...

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

28 avr 2024
Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW),...



News published on and distributed by: